Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

19.87 USD +0.10 (+0.51%)
Official Closing Price Updated: 5:26 PM EDT, Apr 16, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Alkermes Plc

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
24 25 Next >
Alkermes to Present Data on Schizophrenia Portfolio at Upcoming Schizophrenia International Research Society Conference
Alkermes plc (NASDAQ:ALKS) today announced that data from Alkermes’ schizophrenia portfolio will be featured at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference to be... 
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at the Barclays Global Healthcare Conference
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Barclays Global Healthcare Conference on Wednesday, March 16, 2016, at 8:30 a.m. EDT (12:30 p.m.... 
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at the Cowen and Company 36th Annual Health Care Conference
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016, at 9:20 a.m. EST... 
From Business Wire News Releases
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and Provides Financial Expectations for 2016
Alkermes plc (NASDAQ: ALKS) today reported financial results for the twelve months ended Dec. 31, 2015 and provided financial expectations for 2016. 
From Business Wire News Releases
Alkermes Announces Positive Topline Results From Clinical Study of Two-Month Dosing Option of ARISTADA® for Treatment of Schizophrenia
Alkermes plc (NASDAQ: ALKS) today announced positive topline data from a randomized, open-label, pharmacokinetic (PK) study evaluating a two-month dosing interval of ARISTADA® (aripiprazole lauroxil)... 
From Business Wire News Releases
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EST (1:30 p.m. GMT) on Thursday, Feb. 25, 2016, to discuss the company’s fourth quarter and year-end 2015 financial results.... 
From Business Wire News Releases
Who Will Come Out On Top As Flu Season Draws Down
Tags Publishing & Media
From ACCESSWIRE
Alkermes Announces Initiation of Second Phase 3 Study of ALKS 3831 for Schizophrenia
Alkermes plc (NASDAQ: ALKS) today announced the initiation of ENLIGHTEN-2, the second of two core phase 3 studies for ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate... 
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 18th Annual BIO CEO & Investor Conference on Tuesday, Feb. 9, 2016, at 3:00 p.m. EST (8:00 p.m.... 
From Business Wire News Releases
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 7119
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 7119, an oral, investigational drug candidate being developed for the treatment of agitation in patients... 
From Business Wire News Releases
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of Alkermes plc
Levi & Korsinsky announces it has commenced an investigation of Alkermes plc concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. 
From Business Wire News Releases
Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder
Alkermes plc (NASDAQ: ALKS) today announced preliminary topline results from FORWARD-3 and FORWARD-4, the first two of three phase 3 efficacy studies to read out from the comprehensive FORWARD pivotal... 
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at the 34th Annual J.P. Morgan Healthcare Conference
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 12, 2016, at 9:00 a.m. PST (12:00... 
From Business Wire News Releases
Alkermes Announces Achievement of Milestones for CNS Medicines in Proprietary Product and Pipeline Portfolio
Alkermes plc (NASDAQ: ALKS) today announced new developments and milestones related to its proprietary product and late-stage pipeline portfolio of medicines for the treatment of central nervous system... 
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2015 London Healthcare Conference
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2015 London Healthcare Conference on Wednesday, Nov. 18, 2015, at 10:40 a.m. GMT (5:40... 
From Business Wire News Releases
Alkermes’ Corporate Presentation to Be Webcast at the Credit Suisse 24Th Annual Healthcare Conference
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 24th Annual Healthcare Conference on Tuesday, Nov. 10, 2015, at 9:00 a.m. MST... 
From Business Wire News Releases
Alkermes plc Reports Third Quarter 2015 Financial Results
Alkermes plc (NASDAQ: ALKS) today reported financial results for the third quarter of 2015. 
From Business Wire News Releases
Alkermes Announces Positive Clinical Trial Results and Streamlined Registration Pathway for ALKS 8700 for Treatment of Multiple Sclerosis
Alkermes plc (NASDAQ: ALKS) today provided an update on its regulatory strategy and positive clinical trial results for ALKS 8700, a novel, oral monomethyl fumarate (MMF) molecule in development for... 
From Business Wire News Releases
Alkermes to Host Conference Call to Discuss Third Quarter 2015 Financial Results
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (12:30 p.m. GMT) on Thursday, October 29, 2015, to discuss the company’s third quarter 2015 financial results. Management will... 
From Business Wire News Releases
Early Warning Signs of Schizophrenia Are Not Acted on Soon Enough, According to New Survey of Psychiatrists and Caregivers
According to the results of a recent survey of 600 psychiatrists and caregivers of people living with schizophrenia, nearly all (98%) psychiatrists and the vast majority (81%) of caregivers feel that... 
From Business Wire News Releases
ADDING MULTIMEDIA FDA Approves ARISTADA™ for Treatment of Schizophrenia
Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA™ (aripiprazole lauroxil) extended-release injectable suspension for the treatment of... 
From Business Wire News Releases
Stocks Update From Health Care Sector -- DexCom, Alkermes, BioCryst Pharmaceuticals, Anacor Pharmaceuticals and Endologix
From PR Newswire
Active Equities to Watch in the Healthcare Sector -- AstraZeneca, Valeant Pharma, Novartis, Heron Therapeutics and Alkermes
From PR Newswire
Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical Psychopharmacology Annual Meeting
From Business Wire News Releases
Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Published in Journal of Clinical Psychiatry
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast At The Goldman Sachs 36th Annual Global Healthcare Conference
From Business Wire News Releases
Alkermes to Present Clinical Data on ALKS 8700 at Annual Meeting of the Consortium of Multiple Sclerosis Centers
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at the Jefferies 2015 Global Healthcare Conference
From Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at the UBS Global Healthcare Conference
From Business Wire News Releases
Alkermes plc Reports First Quarter 2015 Financial Results
From Business Wire News Releases
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.